公开(公告)号：US20030148493A1

公开(公告)日：2003-08-07

申请号：US10324302

申请日：2002-12-19

Applicant: Genentech, Inc.

Inventor： Thomas G. Warner ,  Mary B. Sliwkowski

IPC: C12N009/24 ,  C07H021/04 ,  C08B037/00 ,  C12P021/02 ,  C12N005/06

CPC classification number: C12P21/005 ,  A61K38/00 ,  C12N9/2402 ,  C12N15/01 ,  C12Y302/01018

Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. Nucleic acid encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase.

公开(公告)号：US20030166020A1

公开(公告)日：2003-09-04

申请号：US10192022

申请日：2002-07-10

Applicant: Genentech, Inc.

Inventor： Edward T. Cox ,  Jennie P. Mather ,  Mary B. Sliwkowski ,  Teresa K. Woodruff

IPC: G01N033/53 ,  G01N033/567 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06 ,  C07K014/705

CPC classification number: C07K14/71 ,  C07K14/51 ,  C07K14/575

Abstract: An isolated TGF-null supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-null supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-null supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

公开(公告)号：US20030077267A1

公开(公告)日：2003-04-24

申请号：US10155407

申请日：2002-05-22

Applicant: Genentech, Inc.

Inventor： John Frenz ,  Steven J. Shire ,  Mary B. Sliwkowski

IPC: A61K038/46 ,  C12N009/22

CPC classification number: C12N9/22 ,  A61K38/00 ,  C12Y301/21001 ,  Y10S435/814 ,  Y10S435/815

Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.